Doses of 100 mg were given if the patient weighed less than 30 kg and 200 mg if heavier, every two weeks for 52 weeks); Dupilumab reduced asthma exacerbations at one year, improved 10% the pre-bronchodilator FEV1, and reduced inflammatory biomarkers such as Thymus and activation-regulated chemokine (TARC), FENO, and total IgE compared to the placebo group. The gene discussed is CCL17; the disease is asthma.